“Immunogenicity and safety of Cervarix HPV-16/18 AS04-adjuvant vaccine against HPV induced cervical cancer in women (15+ years)”, Student Medical Journal, vol. 3, pp. 50–61, Oct. 2024, doi: 10.33178/SMJ.2023.1.5.